
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
************** Join CureDuchenne and Sarepta on March 4 for a webinar discussing the below announcement. CureDuchenne Webinar: Sarepta Therapeutics update on RNA Exon-Skipping program and Patient Support Services In this […]








